• Berenbaum M C. What is synergy?[J]. Pharmaco Rev, 1989, 41(2): 93-141.

  • Bilello J A, Bilello P A, Stellrecht K. Human serum α1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease[J]. Antimicrob Agents Chemother, 1996, 40(6): 1491-1497.

  • Bulgheroni E, Citterio P, Croce F. Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates[J]. J Antimicrob Chemother, 2004, 53(3): 464-468. doi: 10.1093/jac/dkh103

  • Chou T C, Motzer R J, Tong Y. Computerized quantitation of synergism and antagonism of taxol, topotecan, cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design[J]. J Natl Cancer Inst, 1994, 86(20): 1517-1524. doi: 10.1093/jnci/86.20.1517

  • Deminie C A, Bechtold C M, Stock D. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication[J]. Antimicrob Agents Chemother, 1996, 40(6): 1346-1351.

  • Dorr P, Westby M, Dobbs S. Maraviroc (UK427, 857), a potent, orally bioavailable and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity[J]. Antimicrob Agents Chemother, 2005, 49(11): 4721-4732. doi: 10.1128/AAC.49.11.4721-4732.2005

  • Dressler V, Müeller G, Sühnel J. CombiTool -a new computer program for analyzing combination experiments with biologically active agents[J]. Comput Biomed Res, 1999, 32(): 146-160.

  • FDA. 2005. Guidance for Industry : Antiviral Drug Development-Conducting Virology Studies and Submitting the Data to the Agency (DRAFT GUIDANCE). No. 5

  • FDA. 2004. Guidance for Industry: Role of HIV Drug Resistance Testing in Antiretroviral Drug Development (DRAFT GUIDANCE). No. 12

  • Fleury H J, Toni T, Lan N T. Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data[J]. AIDS Res Hum Retroviruses, 2006, 22(4): 357-366. doi: 10.1089/aid.2006.22.357

  • Flexner C W. Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring[J]. Top HIV Med, 2003, 11(2): 40-44.

  • Greco W R, Bravo G, Parsons J C. The search for synergy: a critical review from a response surface perspective[J]. Pharmacol Rev, 1995, 47(2): 331-385.

  • Lin J H, Lu A Y. Role of pharmacokinetics and metabolism in drug discovery and development[J]. Pharmaco. Rev, 1997, 49(4): 403-449.

  • Parkin N T, Schapiro J M. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV[J]. Antivir Ther, 2004, 9(1): 3-12.

  • Prichard M N, Shipman C Jr. A three-dimensional model to analyze drug-drug interactions[J]. Antiviral Res, 1990, 14(): 181-206. doi: 10.1016/0166-3542(90)90001-N

  • Shipman C Jr. Analysis of drug-drug interactions: an overview[J]. Antiviral Res, 1995, 29(): 41-43.

  • Straetemans R, O'Brien T, Wouters L. Design and analysis of drug combination experiments[J]. Biometrical J, 2005, 47(3): 299-308. doi: 10.1002/(ISSN)1521-4036

  • Vergne L, Stuyver L, Van Houtte M. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibility of non-B HIV-1 strains from treatment-naïve patients[J]. J Clin Virol, 2006, 36(): 43-49. doi: 10.1016/j.jcv.2006.01.012

  • White R L, Burgess D S, Manduru M. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob[J]. Agents Chemother, 1996, 40(8): 1914-1918.

  • Witvrouw M, Pannecouque C, Switzer W M. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and post-exposure prophylaxis[J]. Antivir Ther, 2004, 9(1): 57-65.